| Similar Articles |
|---|
 |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.   |
BusinessWeek
October 31, 2005
Gene G. Marcial |
Why Biocryst Has Wings Shares of the pharmaceutical are on fire, soaring from $4.39 a share in early April to $15 on Oct. 19. |
The Motley Fool
July 20, 2007
Andrew R. Vaino |
BioCryst Is for the Birds Fears of bird flu resurrected a drug for this small pharma, and it has some other promising compounds in the pipeline. Based only on its pipeline size, BioCryst should be valued higher. But make no mistake: This is a risky stock. |
The Motley Fool
September 6, 2011
Brian Orelli |
Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game? |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
The Motley Fool
November 14, 2011
Brian Orelli |
Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up. |
The Motley Fool
April 18, 2011
Brian Orelli |
Up 95%! No Anchor Holding Amarin Down The second phase 3 trial of AMR101 deemed a success. |
The Motley Fool
November 30, 2005
Brian Gorman |
Is BioCryst For Real? Investors may have been right about BioCryst, but for the wrong reasons. Investors were clearly betting a lot on a drug that is still in early phase testing and had failed in the past. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
The Motley Fool
December 15, 2010
Brian Orelli |
Beautiful Efficacy, Wrong Pill Lexicon Pharmaceuticals presented beautiful data showing a pill it gave rheumatoid arthritis patients decreased symptoms in 49% of patients. Unfortunately, the pill was a dummy pill with no active ingredient. |
The Motley Fool
October 8, 2010
Brian Orelli |
Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size. |
The Motley Fool
December 14, 2007
Brian Orelli |
An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
The Motley Fool
September 30, 2010
Brian Orelli |
Bristol-Myers' Delayed Steal ZymoGenetics price tag looks more reasonable. |
The Motley Fool
November 8, 2010
Brian Orelli |
No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective. |
The Motley Fool
September 27, 2010
Brian Orelli |
Better Buy: Ariad Pharmaceuticals or Corcept Therapeutics? A battle of drugless companies looking for their first hit. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
The Motley Fool
June 9, 2010
Brian Orelli |
The Drug Passed, but the Stock Fell? Regeneron only bats .500. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
June 3, 2011
Brian Orelli |
FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully. |
The Motley Fool
March 3, 2010
Brian Orelli |
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
The Motley Fool
March 21, 2011
Brian Orelli |
Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug. |
The Motley Fool
April 12, 2011
Brian Orelli |
How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies. |
The Motley Fool
October 1, 2009
Brian Orelli |
Geez, Lighten Up, Mr. Market! Investors dish out undue punishment to Onyx's stock. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
September 10, 2010
Brian D. Pacampara |
A Potential Blockbuster Roars Ahead Johnson & Johnson made a good choice to purchase Cougar Biotechnology. |
The Motley Fool
August 31, 2009
Brian Orelli |
Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it.. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
September 20, 2007
Brian Orelli |
Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note. |
The Motley Fool
August 11, 2010
Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
September 13, 2007
Brian Orelli |
Alfacell's Awkward Wait Waiting for subjects to die is a somber part of the oncology clinical trial process. Alfacell is doing just that in its final phase three trial with its lead cancer drug candidate. Investors take note. |
The Motley Fool
October 6, 2011
Brian Orelli |
Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
September 11, 2007
Brian Orelli |
A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note. |
The Motley Fool
October 12, 2010
Brian Orelli |
Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
May 24, 2010
Brian Orelli |
ASCO Abstracts -- Pops and Drops! Ever since The American Society of Clinical Oncology began posting abstracts on-line -- and before that when they were sent to attendees -- investors have clamored to get a glimpse at the data. Here's your glimpse. |
The Motley Fool
January 7, 2011
Brian Orelli |
A Biotech Roller Coaster Lexicon is back on the upswing. |
